Jul 28, 2022

Featuring a slide presentation and related discussion from Dr Sandy Srinivas, including the following topics:

• Results from the Phase II SALV-ENZA trial evaluating salvage radiation therapy with enzalutamide or placebo for high-risk PSA-recurrent prostate cancer after radical prostatectomy (0:00)
• Updated overall survival outcomes from the ENZAMET trial of enzalutamide for metastatic hormone-sensitive prostate cancer (3:48)
• Genomic alterations associated with overall survival for patients with metastatic castration-sensitive prostate cancer treated with apalutamide or placebo with androgen deprivation therapy in the TITAN study (7:43)
• Three-year overall survival with 177Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer progressing after docetaxel (9:56)
• Further results from the Phase III PROpel trial of abiraterone with olaparib for patients with metastatic castration-resistant prostate cancer (12:32)
• Results from the MAGNITUDE study of niraparib with abiraterone acetate and prednisone for metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (15:39)
• The role of perioperative chemoimmunotherapy in muscle-invasive urothelial carcinoma (18:23)
• Long-term outcomes from the Phase III EV-301 trial: Enfortumab vedotin versus chemotherapy for patients with previously treated advanced urothelial carcinoma (21:44)
• First results from trials of the novel anti-HER2 antibody-drug conjugate RC48 alone and in combination with the anti-PD-1 antibody toripalimab; results from cohorts 3, 4 and 5 of the COSMIC-021 trial evaluating cabozantinib in combination with atezolizumab for urothelial carcinoma (23:12)
• Updated analyses of exploratory endpoints from the KEYNOTE-564 and CheckMate 9ER trials in renal cell carcinoma (RCC) (26:37)
• Updates on tyrosine kinase inhibitor and immune checkpoint inhibitor combination therapy and other novel approaches for patients with RCC (29:08)

CME information and select publications